Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.80 |
| ▸ | TP53 | P04637 | 2/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.80 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.80 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.71 |
| ▸ | HTT | P42858 | 2/20 | 0.71 |
| ▸ | POLB | P06746 | 7/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | CASP6 | P55212 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 6/20 | 0.63 |
| ▸ | RAB9A | P51151 | 4/20 | 0.63 |
| ▸ | MITF | O75030 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nifuraldezone SCHEMBL193102 | 1.00 | LMNA (0.80) | LMNAALDH1A1CYP3A4CYP1A2KDM4E | |
| Nitrofurazone SCHEMBL25417 | 0.89 | LMNA (1.00) | LMNAALDH1A1CYP3A4CYP1A2KDM4E | |
| Nitrofurazone SCHEMBL25416 | 0.89 | LMNA (1.00) | LMNAALDH1A1CYP3A4CYP1A2KDM4E | |
| Nitrofurazone SCHEMBL3681048 | 0.89 | LMNA (1.00) | LMNAALDH1A1CYP3A4CYP1A2KDM4E | |
| Nitrofurazone SCHEMBL28198181 | 0.87 | LMNA (0.97) | LMNAALDH1A1CYP3A4CYP1A2KDM4E | |
| Nitrofurazone SCHEMBL28285714 | 0.86 | LMNA (0.94) | LMNAALDH1A1CYP3A4CYP1A2KDM4E | |
| Furaguanidine SCHEMBL29870771 | 0.83 | LMNA (0.75) | LMNAALDH1A1CYP3A4CYP1A2KDM4E | |
| Nihydrazone SCHEMBL525528 | 0.83 | HTT (1.00) | LMNAALDH1A1CYP3A4CYP1A2KDM4E | |
| Nihydrazone SCHEMBL525529 | 0.83 | HTT (1.00) | LMNAALDH1A1CYP3A4CYP1A2KDM4E | |
| Nitrofurazone SCHEMBL20775188 | 0.83 | LMNA (0.87) | LMNAALDH1A1CYP3A4CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169680-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-06-02 | — | — | US | claimed |
| EP-3912989-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | Institute of Basic Medical Sciences Chinese Academy of Medical Sciences (CN) | 2021-11-24 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20130252945-A1 | AMORPHOUS BIOINORGANIC IONIC LIQUID COMPOSITIONS COMPRISING PHARMACEUTICALS | LOS ALAMOS NAT SECURITY LLC (US) | 2013-09-26 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20120093759-A1 | Medical Devices, Wound Dressings, and Methods for Dressing Wounds | VACHON DAVID J (US) | 2012-04-19 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| WO-2009059191-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EAR CANAL INFECTION AND INFLAMMATION | EVERETT LABORATORIES, INC. (US) | 2009-05-07 | — | — | WO | claimed |
| US-20090111780-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EAR CANAL INFECTION AND INFLAMMATION | EVERETT LABORATORIES, INC. | 2009-04-30 | — | — | US | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | claimed |
| WO-2007044693-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | THE UNIVERSITY OF ALABAMA (US) | 2007-04-19 | — | — | WO | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1578434-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | Point Therapeutics, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20040131628-A1 | Nucleic acids for the treatment of disorders associated with microorganisms | BRATZLER ROBERT L (US) | 2004-07-08 | — | — | US | claimed |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS, INC. | 2004-04-22 | — | — | US | claimed |
| WO-2004004658-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | POINT THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | SLC5A6, PNLIP, IPMK | LMNA 1556/4885ALDH1A1 2937/4885CYP3A4 1130/4885 |
| US-20130252945-A1 | AMORPHOUS BIOINORGANIC IONIC LIQUID COMPOSITIONS COMPRISING PHARMACEUTICALS | MCOLN1, PYM1, MCOLN2 | LMNA 592/4885ALDH1A1 2641/4885CYP3A4 554/4885 |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | BCAT1, BCAT2, APOB | LMNA 250/4885ALDH1A1 2720/4885CYP3A4 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.